(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/090544 A1

(51) International Patent Classification:
C07D 405/04 (2006.01) *A61P 35/00* (2006.01)
A61P 29/00 (2006.01) *A61K 31/4192* (2006.01)

(21) International Application Number:
PCT/EP2021/080276

(22) International Filing Date:
01 November 2021 (01.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2020/080681
02 November 2020 (02.11.2020) EP
PCT/EP2021/053133
10 February 2021 (10.02.2021) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD** [CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH).

(72) Inventors: **BOLLI, Martin**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **GATFIELD, John**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **GRISOSTOMI, Corinna**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **REMEN, Lubos**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **SAGER, Christoph**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH). **ZUMBRUNN, Cornelia**; c/o Idorsia Pharmaceuticals Ltd Hegenheimermattweg 91, 4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: GALECTIN-3 INHIBITING 2-HYDROXYCYCLOALKANE-1 -CARBAMOYL DERIVATIVES



(I)

(57) Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

WO 2022/090544 A1